



| | | | |
|-----------------------------|-----------------------------------|---------------------------|---|
| Catalog Number: | MC11006 | Product Type: | Small Molecule |
| Bio-Activity: | g-secretase inhibitor | CAS #: | 208255-80-5 |
| Research Categories: | Neuroscience, stem cells | Chemical Name: | N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester |
| Solubility: | Soluble in DMSO (up to 18 mg/ml). | Molecular Formula: | C23H26F2N2O4 |
| Purity: | > 98% | Molecular Weight: | 432.46 |
| Format: | Powder | Ship Temp: | Ambient |
| Storage: | -20°C | | |

Application Notes

Description/Data:

DAPT is an inhibitor of γ -secretase (IC50 in human primary neurons = 115 nM for total A β or 200 nM for A β 42 specifically) (1). Oral consumption of DAPT in mice and rats has reduced the amount of A β in brain extract, cerebrospinal fluid and plasma (2,3). DAPT also blocks Notch signaling, promoting neuronal differentiation (4). DAPT has also been shown to enhance iPS cells without the KLF4 and CMYC oncogenes (5).

References:

- 1) Dovey et al. (2001), Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain; *J. Neurochem.* 76 173
- 2) Portelius et al. (2009), Effects of γ -secretase inhibition on the amyloid β isoform pattern in a mouse model of Alzheimer's disease; *Cell Signal.* 5 615
- 3) El Moueddon et al. (2006), Reduction of A β levels in the Sprague Dawley rat after oral administration of the functional γ -secretase inhibitor, DAPT: a novel non-transgenic model for A β production inhibitors; *Curr. Pharma. Des.* 12 1671
- 4) De Smedt et al. (2005), Different thresholds of notch signaling bias human precursor cells towards B-, NK-, monocytic/dendritic, or T-cell lineage in thymus microenvironment; *Blood*, 106 2236

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

5) Ichida et al. (2014), Notch inhibition allows oncogene-independent generation of iPS cells; *Nature Chem. Biol.* 10 632

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RSKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com